Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19116998 | 0.81 | PARP10 (0.32) | — | |
| SCHEMBL18069885 | 0.77 | UGCG (0.43) | CYP3A4CYP17A1CYP11B2CYP11B1KDM1A | |
| SCHEMBL15918986 | 0.75 | SRD5A1 (0.38) | HTR2C | |
| SCHEMBL31394626 | 0.73 | SRD5A1 (0.39) | KDM1ARAB9AHTR2CHTR2A | |
| SCHEMBL18995114 | 0.73 | HTR2C (0.49) | HTR2CKCNH2HTR2A | |
| SCHEMBL18598471 | 0.73 | ESR1 (0.41) | — | |
| SCHEMBL23192806 | 0.73 | HTR2A (0.36) | HTR2CHTR2A | |
| SCHEMBL18474155 | 0.69 | HTR2C (0.38) | HTR2CHTR2A | |
| SCHEMBL1745534 | 0.69 | CYP17A1 (0.55) | CYP3A4CYP17A1CYP11B2CYP11B1KDM1A | |
| SCHEMBL8554662 | 0.69 | HTR1D (0.46) | KDM1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMECEUTICAL INC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMECEUTICAL INC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP17A1 713/4885CYP11B2 1270/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP17A1 713/4885CYP11B2 1270/4885 |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP17A1 713/4885CYP11B2 1270/4885 |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP17A1 713/4885CYP11B2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.